TABLE 2.
Hematological parameters in mice chronically infected with T. cruzi and treated with BZ or BZ+ASA in the acute phase of infection or left untreateda
| Exptl group | Reticulocytes (%) | Eosinophils (μl) | Neutrophils (mm3) |
|---|---|---|---|
| NI | 7 ± 0.2 A | 68 ± 6.1 A | 1,673 ± 87.6 A |
| I-NT | 9 ± 0.4 A | 138 ± 4.5 B | 2,715 ± 146.2 B |
| I-BZ | 9 ± 0.4 A | 134 ± 0.9 B | 2,684 ± 309.7 B |
| I-ASA | 13 ± 0.9 B | 200 ± 5.4 C | 1,497 ± 135.4 A |
| I-BZ+ASA | 10 ± 0.9 A | 149 ± 22.6 B | 1,760 ± 24.8 A,C |
| I-ASA+Boc-2 | 8 ± 0.5 A | 95 ± 31.5 A,B | 2,530 ± 170.2 B,C |
| I-BZ+ASA+Boc-2 | 9 ± 0.4 A | 130 ± 16.3 B | 2,763 ± 244.6 B |
Mice were treated daily with 25 mg/kg benznidazole (BZ), aspirin (ASA), or a combination of BZ and ASA by oral gavage at 2 days postinfection for 30 days. The antagonist Boc-2 (10 μM/kg) was intraperitoneally injected from 1 day postinfection every 48 h for 7 days before ASA treatment. Heart rate (HR) and mean arterial pressure (MAP) were measured using CODA (a mouse tail cuff blood pressure system) at 180 days postinfection. Values are means ± standard errors of the means. Means followed by the same letter are not significantly different (P < 0.05; two-way ANOVA with Tukey posttest). NI, uninfected group; I, infected group.